Bausch + Lomb Corporation (BLCO) AI Stock Analysis

• Market Cap: $4.40B
• Dividend Yield: N/A
• Average Volume (3M): 767.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: 11.94%
• EPS Growth: -6.98%
• Country: US
• Employees: 13,500
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.07
• Shares Outstanding: 353,396,640
• 10 Day Avg. Volume: 612,966
• 30 Day Avg. Volume: 767,002
• PEG Ratio: -3.94
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 31.93
• Enterprise Value/Market Cap: 1.57
• Enterprise Value/Revenue: 0.37
• Enterprise Value/Gross Profit: 2.51
• Enterprise Value/Ebitda: 3.15
• 1Y Price Target: $13.38
• Price Target Upside: 8.52% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 9

• Rating: 57 Neutral
• Price Target: ―

Bausch + Lomb's overall score reflects solid revenue growth and a strong gross margin, but significant challenges in profitability and cash flow. Technical analysis shows bearish trends, while valuation metrics indicate poor earnings performance. The earnings call provided some optimism with growth in key segments, though risks remain from Pharmaceuticals and tariff pressures.

Positive Factors

Prescription Growth

MIEBO's weekly prescriptions grew 98% YoY to 20,086 in 1Q25.

Revenue Growth

The company continued to deliver revenue growth across most segments in 1Q25.

Revenue Guidance

Management raised 2025 revenue guidance to $5.0-$5.1B (up 4.5-6.5% ex-fx) from $4.95-$5.05B.

Negative Factors

Financial Performance

Net loss was $212M, or ($0.60) per share, more than our estimated loss of $59M.

Guidance and Rating

The stock is under pressure after a guidance cut and the reiteration of an underperform rating.

Product Recall Impact

The enVista recall negatively impacts revenue and EBITDA in 2025, despite the issue being resolved and production resuming.

Bausch + Lomb Corporation Business Overview & Revenue Model

Company Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

How the Company Makes Money

Bausch + Lomb makes money through a diversified revenue model centered around its key product categories. The Vision Care segment generates revenue from the sale of contact lenses and lens care products, catering to both individual consumers and eye care professionals. The Pharmaceuticals segment includes prescription and over-the-counter products for the treatment of various eye conditions, contributing significantly to the company's earnings. The Surgical segment derives its income from the sale of ophthalmic surgical devices and instruments, which are used in procedures such as cataract surgery. Bausch + Lomb's revenue streams are supported by its global distribution network and strategic partnerships with healthcare providers and institutions, enabling it to maintain a strong presence in the eye health market.

Bausch + Lomb Corporation Financial Statement Overview

Summary

Bausch + Lomb Corporation shows solid revenue growth and a strong gross margin, but faces significant profitability challenges and cash flow constraints. The balance sheet is stable with moderate leverage, but profitability needs improvement.

Income Statement

Bausch + Lomb Corporation shows a consistent revenue growth trajectory, with a 3.5% increase in TTM. However, the company is facing profitability challenges, as indicated by negative net income margins and a declining EBIT margin. The gross profit margin remains strong at approximately 66.9%, but the company needs to address its operational inefficiencies to improve its overall profitability.

Balance Sheet

The company maintains a solid equity base with an equity ratio of 47.4%, indicating financial stability. However, the debt-to-equity ratio of 0.76 suggests moderate leverage, which could pose risks if profitability does not improve. The return on equity is negative due to net losses, highlighting the need for enhanced operational performance.

Cash Flow

The cash flow analysis reveals a concerning trend with negative free cash flow in the TTM period, indicating challenges in generating cash after capital expenditures. Operating cash flow is positive but declining, with a significant drop in the operating cash flow to net income ratio. The company must improve its cash generation capabilities to ensure long-term sustainability.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
4.83B	4.77B	4.15B	3.77B	3.77B	3.41B
	Gross Profit
2.75B	2.90B	2.50B	2.25B	2.30B	2.13B
	EBIT
87.00M	162.00M	130.00M	207.00M	329.00M	260.00M
	EBITDA
399.00M	614.00M	512.00M	599.00M	762.00M	739.00M
	Net Income Common Stockholders
-490.00M	-317.00M	-260.00M	15.00M	182.00M	-17.00M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
202.00M	305.00M	331.00M	354.00M	174.00M	238.00M
	Total Assets
13.43B	13.47B	13.44B	11.14B	10.82B	11.27B
	Total Debt
4.83B	4.78B	4.56B	2.44B	112.00M	101.00M
	Net Debt
4.63B	4.48B	4.23B	2.08B	-62.00M	-137.00M
	Total Liabilities
7.00B	6.92B	6.52B	4.04B	1.42B	1.28B
	Stockholders Equity
6.36B	6.47B	6.85B	7.03B	9.33B	9.92B
Cash Flow		Free Cash Flow
-167.41M	-59.00M	-198.00M	170.00M	664.00M	263.00M
	Operating Cash Flow
165.60M	232.00M	-17.00M	345.00M	873.00M	522.00M
	Investing Cash Flow
-470.07M	-412.00M	-2.11B	-215.00M	-214.00M	-256.00M
	Financing Cash Flow
196.63M	178.00M	2.08B	81.00M	-712.00M	-232.00M

Bausch + Lomb Corporation Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.33
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLCO, the sentiment is Neutral. The current price of 12.33 is above the 20-day moving average (MA) of 11.75, above the 50-day MA of 11.94, and below the 200-day MA of 16.40, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 56.19 is Neutral, neither overbought nor oversold. The STOCH value of 81.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BLCO.

Bausch + Lomb Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	85 Outperform	$36.98B	27.99	25.81%	0.84%	9.54%	37.23%
COO	69 Neutral	$13.91B	33.81	5.15%	―	6.88%	21.11%
BAX	61 Neutral	$16.09B	136.07	-8.96%	2.17%	-20.17%	-138.32%
BLCO	57 Neutral	$4.40B	―	-5.56%	―	11.94%	-6.98%
XRAY	56 Neutral	$3.19B	―	-34.47%	4.09%	-5.61%	-921.99%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
STAA	54 Neutral	$863.74M	55.81	-19.14%	―	-14.44%	-557.38%

Bausch + Lomb Corporation Corporate Events

Bausch + Lomb Launches €600 Million Notes Offering

On June 10, 2025, Bausch + Lomb Corporation announced the launch of a €600 million senior secured floating rate notes offering by its subsidiaries, alongside a partial refinancing of its credit agreement. The company plans to use the proceeds to repay existing borrowings and refinance outstanding loans, with the transactions subject to market conditions. The notes will be guaranteed by Bausch + Lomb and secured by first priority liens, though there is no assurance of successful completion.

The most recent analyst rating on (BLCO) stock is a Hold with a $13.38 price target. To see the full list of analyst forecasts on Bausch + Lomb stock, see the BLCO Stock Forecast page.

Bausch + Lomb Launches €600M Notes Offering

On June 10, 2025, Bausch + Lomb Corporation announced the launch of a €600 million senior secured floating rate notes offering by its subsidiaries, alongside a partial refinancing of its credit agreement. The company aims to secure a $2.2 billion new term B loan facility and a new $800 million revolving credit facility to refinance existing loans and support general corporate purposes. The transactions, subject to market conditions, are designed to strengthen the company’s financial structure but are not guaranteed to be completed as planned.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb Launches €600 Million Notes Offering

On June 10, 2025, Bausch + Lomb Corporation announced the launch of a €600 million senior secured floating rate notes offering by its subsidiaries, alongside a partial refinancing of its credit agreement. The company plans to use the proceeds to repay existing borrowings and refinance outstanding loans, with the transactions subject to market conditions. The notes will be guaranteed by Bausch + Lomb and secured by first priority liens, though there is no assurance of successful completion.

The most recent analyst rating on (BLCO) stock is a Hold with a $13.38 price target. To see the full list of analyst forecasts on Bausch + Lomb stock, see the BLCO Stock Forecast page.

Bausch + Lomb Shareholders Approve Executive Compensation

At the Annual Meeting of Shareholders on May 21, 2025, Bausch + Lomb Corporation‘s shareholders voted on three proposals. The election of directors resulted in the appointment of several individuals to the Board of Directors, who will serve until the 2026 Annual Meeting. Additionally, the shareholders approved the executive compensation on a non-binding advisory basis.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb’s New Board Agreements Announced

On May 19, 2025, Bausch Health Companies Inc., the majority shareholder of Bausch + Lomb Corporation, entered into letter agreements with the Icahn Group, Paulson Group, and Kavanagh Group. These agreements stipulate that if any of these groups engage in specified actions, they must resign from the boards of both Bausch Health and Bausch + Lomb. The agreements also include provisions for voting on board nominees, aiming to maintain stability in board representation.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.